🇯🇵·13h agoIndustry
Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D- Mutated Advanced Non-Small Cell Lung Cancer
Publisher
A
Astellas Pharma
Japan
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Astellas Pharma
- Region
- Japan
- Scope
- Industry
- Published
- September 24, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on newsroom.astellas.com
Leave the platform to read the original full article on the publisher site.
Source: Astellas Pharma
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News/2h ago
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
Interpharma Switzerland/6h ago
Klinische Forschung unter Druck: Die Schweiz verliert den Anschluss
Chugai Pharmaceutical News/6h ago
ロシュ社によるセーファキセルセンナトリウムに関する発表について（第III相IMAGINATION試験の中間解析結果）
Chugai Pharmaceutical/6h ago